Skip to main content

is part of the Informa Markets Division of Informa PLC

  • INFORMA PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Eurogin
 

08 - 11 February 2023

Bilbao, Spain

  • 
  • Scientific Information
    • Message from the Chairman of the Scientific Committee
    • Previous Congress Presidents
    • Previous Congresses
  • Program & CME
    • Program Overview
    • Download Program 2022
    • CME Accreditation
  • Registration
    • SOD Add-on
  • Abstracts & Posters
    • Abstracts EUROGIN 2022
  • Sponsorship & Exhibition
    • Sponsors and Exhibitors 2022
    • Exhibitors Information
    • Previous Meeting Reports
  • Congress Information
    • Contact us
    • Newsletter
    • Post Meeting Report 2022
    • Picture Gallery 2022

Abstract Information

NEW ABSTRACT SUBMISSION DEADLINE: DECEMBER 15, 2021

Late breaker deadline : on request – strict conditions to be complied with.

All abstracts must be submitted through the online abstract submission system.

General conditions for submission of abstracts

Submission of an abstract implies the commitment that the presenting author registers for the EUROGIN 2022 Congress and has adequate financial resources to attend.

  1. Authors are requested to register within 10 days after having received their provisional notification of acceptance.

    Abstract presenters who would like to benefit from the super early bird registration rate (deadline is December 1, 2021) are advised to submit their abstract before November 15, 2021 and send a short notice to [email protected]

    They will then receive notification of acceptance/refusal which will allow them to register at the super early bird rate.

    If the abstract presenter is registered with a group, please inform the Congress Secretariat at: [email protected] and indicate the person who booked the group registration;

  2. Abstracts must be submitted and presented in ENGLISH;

  3. Abstracts should be prepared in accordance to the instructions below and submitted through the online system. Abstracts should comply with the editing instructions;

  4. For proffered papers (for Free Communications sessions or Poster presentation), only ONE abstract is allowed per person duly registered for the congress;

  5. Original scientific material is welcome and preference is given to recent findings not yet published at the date of the Congress;

  6. Abstracts will be peer reviewed and evaluated by experts in one of the categories (topics) listed; they will be allocated for oral or poster presentation. Authors who do not wish to be considered for oral presentation are requested to indicate this when submitting. However, please note, that the Scientific Committee will make the final decision for the mode of presentation;

  7. The final decision of the Scientific Committee will be announced early 2022;

  8. Authors agree that their abstract will be published in the congress abstract book (pdf document, no printed document will be issued)

  9. All accepted abstract submitters will receive confirmation by email. Please do not forget to indicate your correct email address and telephone number when submitting your abstract, as well as the email addresses of the main author and the presenter (the author who will present the paper at the conference).
    The main author and the presenter can be the same person. They may also be identical to or different from the submitter);

  10. The main author and the presenter must be identified (by ticking the corresponding boxes);

  11. For further information and assistance please contact the scientific secretariat at [email protected]

Abstract editing instructions

  1. Abstracts must be submitted through the online submission system;

  2. Maximum length (body of abstract): 2700 characters (spaces included);

  3. The title should be written in UPPER CASE (capitals); (keep it as short as possible, clearly indicating the nature of the investigation;

  4. Please avoid complex mathematical formulae; the system allows to insert simple tables;

  5. Abstracts should be structured in at least three sections, clearly mentioned as such: Background/Objectives – Methods – Results (optional) – Conclusions. References may be mentioned;

  6. All authors (main author and co-authors) should be listed with their last names (family names) and their first name(s). The published version will only mention the initial(s) of the first name(s).ONE author must be identified as the PRESENTER; the presenter commits to registering as a delegate (except if she/he is an invited speaker), to attend the congress and present the abstract;

  7. Please indicate professional addresses of all authors: Name of hospital, unit or laboratory, city and country in lower case. No other indications are to be given. Different affiliations will be automatically numbered;

  8. Do not indent spaces on the first line of each paragraph. No space should be inserted between paragraphs. Use international standards for scientific articles;

  9. Only standard abbreviations may be used without definition. Data must be given in units widely used in literature;

  10. Only essential references should be included and put in brackets at the end of the abstract: Numbers in the text may refer to them;

  11. Drugs must be identified by their generic names and no company names should be mentioned in the title of the abstract.

Abstract topics

For review purposes, abstracts are classified according to the following list.

Select only 1 topic on our submission form:

  1. HPV disease and COVID-19
  2. Viral and molecular biology
  3. Epidemiology and natural history
  4. Pathogenesis
  5. Immunology
  6. HPV prophylactic vaccines
  7. HPV therapeutic vaccines
  8. Immunotherapy - Immuno-oncology - New treatments
  9. HPV testing
  10. HPV screening
  11. Screening for women difficult to reach
  12. Triage of HPV positive women
  13. Self-sampling
  14. Genotyping
  15. Molecular markers
  16. Screening methods
  17. Automation in cytology
  18. Methylation
  19. Microbiome
  20. Serology
  21. New technologies
  22. Artificial Intelligence
  23. Diagnostic procedures / management
  24. Risk management
  25. Colposcopy
  26. Cervical neoplasia
  27. Vulvar and vaginal diseases and neoplasia
  28. Anal neoplasia
  29. Oral HPV infection
  30. HPV and oropharynx / Head and neck cancer
  31. HPV and associated skin diseases
  32. Genital warts
  33. HPV transmission
  34. Sexually transmitted diseases and HIV infection
  35. Conventional therapies
  36. Economics and modelling
  37. Advocacy, acceptability and psychology
  38. Health education
  39. Low resource settings
  40. Public health
  41. Fertility and HPV

ABOUT EUROGIN

EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) brings together clinicians and scientists whose work is related to genital infections and neoplasia.

ETHICAL COMPLIANCE

EUROVIR, owning the trademark EUROGIN, is a Trusted Partner of Ethical MedTech.

USEFUL LINKS

  • Registration Information |
  • EUROGIN PORTAL |
  • EUROGIN FRANCE |
  • Previous events |
  • Related Events / Partnerships |
  • Legal Information |
  • Cancellation Policy |
  • Delegates Terms & Conditions
Informa Markets

Copyright © 2022. All rights reserved. Informa Markets, a trading division of Informa PLC.

  • Accessibility|
  • Privacy Policy |
  • Cookie Policy|
  • Terms of Use|
  • Visitor Terms And Conditions